Clinical Trial: Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024862) titled 'Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy' on June 09.

Brief Summary: The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) <1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

Study Start Date: Oct. 24, 2024

Study Type: OBSERVATIONAL

Condition: Metastatic Non-small Cell Lung Cancer

Intervention: BIOLOGICAL: nivolumab + ipilimumab

Firs...